New Data from NCSI Demonstrates 72% Survival with 98% Native Heart Recovery

New data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients...

Dr. Seth Bilazarian on the recent Circulation paper by Dr. Schrage/Dr. Ibrahim

Dr. Seth Bilazarian discusses a recent paper published in Circulation by Drs. Benedikt Schrage, Karim Ibrahim, et. al....

Analysis of Outcomes for 15,259 U.S. Patients with AMICS Supported with the Impella Device

Dr. William O’Neill outlines his recent publication of 15,529 AMI cardiogenic shock patients from the Impella Quality (IQ) da...

How to Better Evaluate, Identify and Manage Shock Patients

Recently, Abiomed’s platform of Impella® heart pumps received FDA approval for the treatment of patients experiencing cardio...

Significance of FDA Approval of Impella for Cardiogenic Shock

Listen to Dr. William W. O’Neill, Medical Director for the Center for Structural Heart Disease at Henry Ford Hospital, discus...

Roundtable Discusses Protected PCI for High-Risk Patients

In the video below, Dr. John Lasala from Washington University, St. Louis, Missouri, hosts a roundtable discussion on Protected...

New Insights from PROTECT II Trial Discussed at TCT 2011

Hemodynamic Support in High Risk Patients Undergoing Extensive Revascularization: Dr. John Lasala, Dr. Jeff Moses, Dr. Bill O'N...

Protected PCI Offers New Option for Patients Turned Down for CABG or Traditional PCI

Improving the health of patients and offering the best possible treatments is the primary ethos and goal of any medical profess...

About This Site

Welcome to the Protected PCI community, the largest source of education and reference materials on pVADs and the Impella® plat...

About Impella

Provides direct left ventricular unloading by pulling blood from the left ventricle and expelling it into the aorta, incr...

Editorial Board

Editorial Board Members  ...